admission date: [2185-1-3]        discharge date: [2185-1-15]date of birth:  [2124-7-21]        sex:  mservice:  medhistory of present illness:  mr. [known lastname ] is a 60-year-old malewith metastatic melanoma, admitted to begin cycle 1, week 1high-dose il-2 therapy. his oncologic history began in [2184-7-27], when he noted a right groin skin tag which grew quicklyover 2 months. excisional biopsy in [2184-10-27] revealed agreater than 11 mm thick, ulcerated melanoma with perineuralinvasion and mitotic rate of 8 per meters squared. he wasreferred to cutaneous [hospital ] clinic, at which point 2subcutaneous nodules along the right groin scar were notedand a left posterior shoulder subcutaneous nodule was noted.fine needle aspiration confirmed a melanoma at the site. petct revealed widespread metastases in the lung, liver,subcutaneous tissues and bone. brain mri was negative. he wasevaluated for high-dose il-2 and passed eligibility testingto begin therapy.past medical history:  bph, status post laparoscopiccholecystectomy in [2178], left knee arthroscopic surgerycomplicated by left dvt, hypertension, sleep apnea,osteoarthritis of the right knee, melanoma as above, benignpositional vertigo, history of pseudogout, history of c-7narrowing with occasional nerve pain.allergies:  no known drug allergies.medications:  lisinopril 20 mg daily, on hold, flomax 0.4 mgdaily, proscar 5 mg daily, naprosyn 500 daily to b.i.d.p.r.n.physical examination:  general:  well-appearing male in noacute distress. performance status 1. vital signs: 97.5, 130,18, 133/80, o2 saturation 94% in room air. heent:normocephalic, atraumatic. sclerae anicteric. moist oralmucosa without lesions, multiple scalp nodules present. neck:supple. lymph nodes: no cervical, supraclavicular, bilateralaxillary or bilateral inguinal lymphadenopathy. right groinsubcutaneous nodules noted. heart:  regular rate and rhythm,s1 and s2. chest:  clear to percussion and auscultationbilaterally. abdomen:  rounded, positive bowel sounds, soft,nontender, no hsm or masses. extremities:  no lower extremityedema. neuro exam: nonfocal. skin: right groin biopsy sitehealed without nodularity. there are subcutaneous nodulesabove and below the biopsy site as well as scattered scalpnodules. there is a left shoulder subcutaneous nodulemeasuring approximately 4 x 3 cm and a left low axillarychest wall subcutaneously nodule measuring approximately 1cm.admission labs:  wbc 10.6, hemoglobin 11.7, hematocrit 34.5,platelet count 237,000, inr 1.2, bun 20, creatinine 1, sodium138, potassium 4.5, chloride 99, co2 24, glucose 138, alt 40,ast 41, ldh 970, alkaline phosphatase 179, amylase 35, totalbilirubin 0.8, lipase 39, albumin 3.8, calcium 9.3,phosphorus 3.6, magnesium 2.3.hospital course:  mr. [known lastname ] was admitted and underwentcentral line placement to begin therapy. his admission weightwas 106.6 kg, and he received interleukin-ii 600,000international units per kilogram, equaling 64 million unitsiv q.8h. x14 potential doses. during this week, he received10 of 14 doses, with 1 dose held for questionableneurotoxicity and 3 doses held due to development oftachypnea, stridor and respiratory distress, requiringmechanical ventilation. this event occurred in early morninghours of treatment day #5 and he was transferred emergentlyto the icu and intubated, given stridor and tachypnea. he wasnot having significant hypoxia at this time. he then becamehypotensive, requiring initiation of phenylephrine andlevophed. at the time of his intubation, his bicarbonate was15 and he was aggressively treated with bicarbonaterepletion. the patient was intubated x4 days and waseventually extubated on [1-11]. he continued to recoverand was recovering was transferred back to the floor on[1-12], where rehab was initiated. he developedclostridium difficile diarrhea, improved on flagyl. he waseventually discharged to home on [2185-1-15] withphysical therapy.other side effects during il-2 therapy included mild chills;development of an erythematous skin rash; nausea, improvedwith lorazepam; diarrhea, improved with lomotil, and fatigueduring this week, he developed acute renal failure with apeak creatinine of 7.3, improved to 1.3 at the time ofdischarge. he developed hyperbilirubinemia with a peakbilirubin of 7.1, improved to 1.1 upon discharge. he alsodeveloped transaminitis with a peak alt of 100 and peak astof 117, improved to within normal limits at the time ofdischarge. he was anemic with hemoglobin of 7.2, improved to11.7 after packed red blood cell transfusion. he wasthrombocytopenic with a platelet count low of 55,000, withoutevidence of bleeding. as noted above, he developed metabolicacidosis, felt to be at least partially responsible for hisrespiratory failure, with a minimum bicarbonate of 14,improved with bicarbonate repletion. he had no evidence ofcoagulopathy or myocarditis. by [2185-1-15] he wasdischarged to home.condition on discharge:  stable.discharge diagnosis:  metastatic melanoma, status post cycle1, week 1 high-dose il-2 complicated by respiratory failureand acute renal failure.discharge medications:  lorazepam 1 mg q.4-6h. p.r.n.nausea/vomiting, compazine 10 mg q.6h. p.r.n.nausea/vomiting, proscar 5 mg daily, flagyl 500 mg p.o.t.i.d. oxycodone 5 to 10 mg q.4h. p.r.n. pain, zantac 150 mgp.o. t.i.d.followup plans:  mr. [known lastname ] will be seen in clinic in 1 weekand the 2nd week of il-2 therapy will be determined at thattime.                        [first name11 (name pattern1) ] [last name (namepattern4) 26819], [md number(1) 26820]dictated by:[last name (namepattern1) 18853]medquist36d:  [2185-4-1] 16:17:52t:  [2185-4-3] 09:22:18job#:  [job number 69910]cc:[numeric identifier 69911][first name8 (namepattern2) ] [last name (namepattern1) 29848], md[first name (titles) ] [last name (titles) 159] associates50 [location (un) 69912], [numeric identifier 43858]